Clinical Trials
13 trialsNCT05262335 2023-11-28
ALTER-G-001
Ruijin Hospital
Phase 2 Unknown
NCT04962958 2023-06-22
Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT05913661 2023-06-22
Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT04960943 2021-07-14
Efficacy and Safety of Pyrotinib in HER2 Positive Gastrointestinal Tumors
Fudan University
Phase 2 Unknown
NCT04207463 2020-06-17
A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Unknown
NCT03271255 2019-01-23
Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C)
Shenzhen People's Hospital
Phase 2 Unknown
NCT01037049 2018-09-17
Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks
Royal Marsden NHS Foundation Trust
Phase 2 Unknown
NCT02215837 2016-05-24
Study of Autologous Tumor Lysate-pulsed D-CIK Combined With Chemotherapy for Gastric Cancer
Shenzhen Hornetcorn Bio-technology Company, LTD
Phase 2 Unknown
NCT02487017 2016-05-24
DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma
Shenzhen Hornetcorn Bio-technology Company, LTD
Phase 2 Unknown
NCT02644863 2016-05-24
Autologous Tumor Tissue Antigen-sensitized DC-CIK Cells Combined With Chemotherapy for Esophageal Cancer
Shenzhen Hornetcorn Bio-technology Company, LTD
Phase 2 Unknown
NCT02202928 2015-12-28
Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal Cancer
Shenzhen Hornetcorn Bio-technology Company, LTD
Phase 2 Unknown
NCT02356406 2015-02-06
Celiac Plexus Radiosurgery for Pain Management
Sheba Medical Center
Phase 2 Unknown
NCT01556815 2012-04-25
Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma
Shandong Cancer Hospital and Institute
Phase 2 Unknown